5395232022-07-012022-09-305395232022-09-305395232022-03-315395232022-04-012022-09-305395232022-07-012022-09-30in-bse-fin:OtherExpenses1Member5395232022-04-012022-09-30in-bse-fin:OtherExpenses1Member5395232022-07-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss15395232022-04-012022-09-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares539523ALKEMNOTLISTEDINE540L01014ALKEM LABORATORIES LIMITEDEquity2022-04-012023-03-312022-11-112022-11-02INRMillionsHalf yearlySingle segmentThe Company is exclusively engaged in pharmaceutical business2022-11-1111:00:002022-11-1113:15:00trueCash Flow IndirectNot applicable2022-07-012022-09-30UnauditedStandalone24614900000736400000253513000006748100000255350000012438000004129700000200200000577400000588300000021335700000401560000004015600000699800000-1911000005087000000350690000000003506900000-4100000350280000000239100000229.3329.330029.3329.331. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 10 November 2022 and subsequently approved by the Board of Directors at its meeting held on 11 November 2022. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2022. <BR> <BR> 2. During the quarter ended 30 September 2022, the Company paid a final dividend of Rs. 4 (Rupees four only) per equity share (200% on the face value of Rs. 2 each) for the financial year 2021-22. <BR> <BR> 3. The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.2022-04-012022-09-30UnauditedStandalone451984000001289500000464879000001282120000043926000002511500000800000000042040000011455000001158320000040874400000561350000005613500000974900000-2693000007056000000490790000000004907900000-8200000489970000000239100000241.04841.0480041.04841.048Other expenses5883000000Other expenses1158320000016841800000275690000000157690000024703300000833000001213000000259996000001076100000087900000058815200000173519000001191500000201858000002416000002274400000019500000018902000004644810000005434500000692345000001280497000002391000009161900000091858100000918581000000474000000474000000353750000061700000407320000015373100000946830000046093000002945070000012514000001416300000032118400000361916000001280497000001. The above unaudited standalone financial results of the Company were reviewed and recommended by the Audit Committee on 10 November 2022 and subsequently approved by the Board of Directors at its meeting held on 11 November 2022. The auditors have issued an unmodified report on the financial results for the quarter and six months ended 30 September 2022. <BR> <BR> 2. During the quarter ended 30 September 2022, the Company paid a final dividend of Rs. 4 (Rupees four only) per equity share (200% on the face value of Rs. 2 each) for the financial year 2021-22. <BR> <BR> 3. The Company operates in one reportable business segment i.e. "Pharmaceuticals", accordingly no separate disclosure of segment has been made.4204450002405400000-18598300000-4077830000000-154109400000011455000000340735000000-3554050003630000070407900000005221500000-54019600050733040000009826540000409065000000000000778500088095200000000000000-3361150000000036300000519103000042355530003581674000000000000737195200006218500047830000033649100000-8248928000-5766040000-576604000818200000241596000Remeasurements of defined benefit plans-6300000-6300000Remeasurements of defined benefit plans-12600000-12600000-2200000-440000000